Daewoong Nabota is expected to take a global leap

Forward due to the expansion of treatment indications

The largest toxin market competes with Allergan Botox in the United States in the treatment field

Apply for a square jaw improvement indication

Clinical progression of inflammable migraine and cervical muscle tension abnormalities

As Daewoong Pharmaceutical's botulinum toxin product Nabota (Jubo·Jeubeau) is likely to surpass 100 billion won in sales this year, it is drawing attention as it is expanding its global scope as a representative K-toxin product.

 

Nabota, which was launched in Korea in 2014, recorded 15.1 billion won in 2019 It achieved sales of 79.6 billion won last year after Quantum Jump, 233% sales of 50.4 billion won the following year.

 

After the FDA approved the final item license in February 2019, it began to target the North American market in May of the same year.

 

The U.S.

 

occupies 50% of the global toxin market worth 6 trillion won, and Allergan Botox products are leading the treatment, beauty, and plastic surgery market.

 

Europe is the second-largest market for toxin drugs, and Nabota is expected to be launched in the second half of this year.

 

Item licenses in China, which are highly regarded for its rapid growth and potential market value, are also expected to be approved as early as this year, and full-fledged releases and profits are expected from next year.

 

Evolus is in charge of the beauty business partners in the U.S., Europe, Australia, and Canada, while Ion Biopharma is in charge of the treatment business partners in the U.S.

 

Currently, Nabota is in charge of production at the first plant of Hyangnam Pharmaceutical Complex, and when the second plant is completed in 2025, it is expected to become a global leading company as it can produce a total of 5 million vials per year.

 

As of September 2022, Nabota's indications include eyelid wrinkles, eye wrinkles (abnormal beauty), improvement of upper extremity muscle stiffness after stroke, and eyelid cramps (abnormal treatment).

 

As for the progress of additional indications, it is waiting for approval after submitting approval to the MFDS in April 2022 for the world's first item permission to add positive adiabatic hypertrophy (square jaw improvement).

 

In addition, phase 2 clinical trials for chronic and inflammatory migraine and cervical muscle tension are underway in the United States, Canada, and Australia.

 

A panoramic view of Nabota

Chronic migraine headaches account for 40% of the total treatment market, and there is no competition other than Botox yet.

 

If Nabota enters this field, it is expected to penetrate the market quickly based on price competitiveness.I t is also preparing clinical trials for gastric paralysis indications, which do not yet have a clear treatment.

 

It is predicted that a new treatment paradigm can be provided in a unique way by injecting toxin directly into the upper and lower parts of the stomach through endoscopy.

 

In addition to the three global toxin markets, plans to release them in niche markets such as Turkey, Chile, Peru, Saudi Arabia, Egypt, and Indonesia are also drawing attention.

 

Nabota is a premium toxin brand based on high-pure technology patent technology.

 

An official from Daewoong Pharmaceutical said, "Nabota is the only product in Asia that has been approved for sales in the United States, Europe, and Canada." "We plan to expand our markets in the U.S., Europe, and China through aggressive investment in the future," he said.

 

Meanwhile, Nabota's ITC lawsuit disappeared in February last year when Daewoong Pharmaceutical's U.S.

 

partner Evolus signed a three-way agreement with AbbVie and Medy Tox, and has since grown rapidly based on U.S.

 

exports.

 

Of Nabota's overseas sales in the second quarter, exports to the U.S.

 

through Evolus amounted to 21.1 billion won, which doubled from the same period last year.